CORC

在结果中检索

CORC

浏览/检索结果: 共217条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety 期刊论文
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2022, 页码: 9
作者:  Zhang, Jingfang;  Li, Wenzhe;  Qi, Yafei;  Wang, Guorong;  Li, Lele
收藏  |  浏览/下载：11/0  |  提交时间：2023/02/22
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors 期刊论文
BMC Medicine, 2022, 卷号: 20, 期号: 1
作者:  Zhang,Pei;  Du,Yang;  Bai,Hua;  Wang,Zhijie;  Duan,Jianchun
收藏  |  浏览/下载：123/0  |  提交时间：2022/11/21
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor 期刊论文
THORACIC CANCER, 2022
作者:  Wang, Wenxian;  Wang, Qian;  Xu, Chunwei;  Li, Ziming;  Song, Zhengbo
收藏  |  浏览/下载：32/0  |  提交时间：2022/12/23
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial 期刊论文
BRITISH JOURNAL OF CANCER, 2022
作者:  Qin, Shukui;  Li, Jin;  Zhong, Haijun;  Jin, Chuan;  Chen, Lili
收藏  |  浏览/下载：21/0  |  提交时间：2022/12/22
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry 期刊论文
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 卷号: 15
作者:  Liu, Long;  Yu, Xingxing;  Li, Zhifeng;  He, Xiaohua;  Zha, Jie
收藏  |  浏览/下载：227/0  |  提交时间：2022/12/23
Ratiometric co-delivery of hydroxychloroquine and calculated low-dose paclitaxel efficiently suppresses tumor growth in hepatocellular carcinoma mouse models in vivo 期刊论文
NANO TODAY, 2022, 卷号: 44
作者:  Wang, Wenbin;  Sun, Hui;  Gong, Yan;  Liu, Xiangsheng;  Liu, Xiao
收藏  |  浏览/下载：116/0  |  提交时间：2022/12/23
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Wang, Jing;  Lou, Hanmei;  Cai, Hong-Bing;  Huang, Xin;  Li, Guiling
收藏  |  浏览/下载：16/0  |  提交时间：2022/12/23
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis 期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng
收藏  |  浏览/下载：29/0  |  提交时间：2022/05/05
Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Lin, Yuxin;  Zhu, Wei;  Wu, Bingchen;  Lan, Huiyin
收藏  |  浏览/下载：22/0  |  提交时间：2022/05/16
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial 期刊论文
LANCET ONCOLOGY, 2022, 卷号: 23
作者:  Zhou, Qing;  Chen, Ming;  Jiang, Ou;  Pan, Yi;  Hu, Desheng
收藏  |  浏览/下载：104/0  |  提交时间：2022/03/21

©版权所有 ©2017 CSpace - Powered by CSpace